Feasibility and acceptability of remote activity and patient-reported outcome monitoring in men with prostate cancer undergoing androgen deprivation therapy.

• DOI: 10.1200/jco.2025.43.16_suppl.e17090
• Publication Date: 2025-05-28T16:28:13Z
• Authors: Brandon Noorvash; Aubrey Jarman; Haleigh Bellerose; Katherine Barnhill; Tyra Nguyen; Carolina Raines; Jun Gong; Howard M. Sandler; Edwin Melencio Po...; Celina H. Shirazi...; Stephen J. Freedland; Gillian Gresham

e17090

Background: ADT, a standard treatment for prostate cancer (PC), is associated with significant side effects such as fatigue, muscle loss, weight gain, and mood changes, which can lead to physical function decline and poor quality of life. Wearable technology for continuous activity monitoring combined with routine patient-reported outcome (PRO) collection may provide a more complete and accurate picture of a patient’s treatment experience, offering valuable information for guiding symptom management. This study aimed to evaluate the feasibility and acceptability of remote patient monitoring with wearable technology and PROs in men diagnosed with PC undergoing ADT. Methods: Men diagnosed with PC undergoing ADT, recruited from two healthcare facilities as part of the DigiPRO trial (NCT04575402), wore an activity monitor (Fitbit Charge HR) continuously to monitor daily activity and sleep and completed monthly electronic PROs (NIH PROMIS and PRO-CTCAE) over a 12-week study period. Feasibility was defined as >60% of patients adhering to wearing the device and completing PROs at the 12-week primary study endpoint. Acceptability was also assessed through qualitative interviews among a subset of patients, gathering feedback on the usability and impact of the wearable devices. Additionally, a survey was conducted among clinicians with experience treating PC patients to assess their interest in accessing and using the wearable and PRO data. The proportion of patients adhering to wearing the devices and completing PROs at 12 weeks was calculated. Descriptive statistics were computed to summarize clinician survey responses, and inductive thematic analysis was applied to patient interview data. Results: All 40 PC participants (100%) (Median age: 70 years, range 51-87, 60% White/37% Black) consistently used the monitoring devices and 38 participants (95%) completed monthly PROs over the 12-week period. From the interviews, patients reported that the devices were easy to use and enjoyed wearing them to monitor their PA and sleep. Clinicians expressed overall support for accessing the device data, where 7/10 clinicians responded that they would access patient wearable activity data in the medical chart and believe EMR-integrated wearable activity data would help them better take care of patients. Conclusions: Our findings suggest that remote activity and PRO monitoring are feasible and acceptable for PC patients, with high device adherence, PRO completion, and perceived benefits of use observed by clinicians and patients. Clinicians and researchers should consider incorporating remote activity and PRO monitoring into future research studies.

Clinical trial information: NCT04575402

.